Post menopausal bleeding is not always cancer. In fact, only about 9% of women who experience bleeding after menopause are ultimately diagnosed with endometrial cancer. The most common cause, by a wide margin, is tissue thinning from low estrogen levels, which accounts for roughly 60% of cases. That said, any bleeding after menopause deserves prompt evaluation because it is the earliest and most recognizable warning sign of uterine cancer when cancer is present.
What Causes Most Postmenopausal Bleeding
Once your periods have stopped for 12 consecutive months, any vaginal bleeding counts as postmenopausal bleeding. The overwhelming majority of cases trace back to something benign. Genitourinary atrophy is the single biggest cause. After menopause, declining estrogen thins the vaginal lining and the tissue inside the uterus. The vaginal walls lose elasticity, blood flow decreases, and the tissue becomes fragile enough to bleed from minor friction, including sexual intercourse. This is sometimes called genitourinary syndrome of menopause, and it’s extremely common.
Endometrial polyps are another frequent culprit. These are small, usually noncancerous growths on the uterine lining. In studies of postmenopausal women with polyps and bleeding, over 80% of the polyps turned out to be benign on biopsy, though a small percentage (around 7%) were associated with endometrial tumors. That’s why polyps found during an evaluation are typically removed and tested rather than left alone.
Other benign causes include uterine fibroids, infections of the vagina or cervix, endometrial hyperplasia (a thickening of the uterine lining that can be precancerous but often isn’t), and medications. Blood thinners, for example, can trigger unexpected bleeding. Tamoxifen, a drug used in breast cancer treatment, is also a well-known cause.
How Hormone Therapy Plays a Role
If you’re taking hormone replacement therapy, bleeding may simply be a side effect. Cyclic hormone therapy, where you take estrogen daily and a progestin for 10 to 14 days each month, commonly causes monthly bleeding that can range from light spotting to something resembling a regular period. This type of breakthrough bleeding often resolves within six months of starting treatment.
Among women on hormone therapy who develop postmenopausal bleeding, the rate of endometrial cancer diagnosis drops to about 7%, compared to 12% in women not using hormones. That doesn’t mean you should ignore bleeding while on hormone therapy, but it does shift the statistical odds toward a benign explanation.
Who Faces Higher Cancer Risk
Certain factors make it more likely that postmenopausal bleeding has a malignant cause. Obesity is one of the strongest. Fat tissue produces estrogen, and prolonged exposure to estrogen without the balancing effect of progesterone drives the growth of uterine lining cells. Women who have both diabetes and obesity face a dramatically higher risk. One large study found that women with diabetes alone had about 1.4 times the risk of endometrial cancer, but adding obesity to the equation pushed the risk to more than five times higher than average.
Other factors that increase risk include starting periods early, going through menopause late, never having been pregnant, having high blood pressure, thyroid disease, or a family history of uterine or colon cancer. Women with Lynch syndrome, a hereditary condition, carry the highest genetic risk. Depending on the specific gene mutation involved, lifetime risk of endometrial cancer can range from 17% to as high as 71%.
What Happens During Evaluation
The standard first step is a transvaginal ultrasound, which measures the thickness of your uterine lining. In postmenopausal women, a lining of 4 millimeters or less is generally considered reassuring. When the lining is thicker than that, or when the ultrasound shows irregular features like uneven texture or increased blood flow, further testing is recommended.
That next step is usually an endometrial biopsy. The most common office-based tool is a thin, flexible catheter (often called a Pipelle) inserted through the cervix to collect a small tissue sample. It takes a few minutes, can cause cramping similar to a bad period, and provides results within a week or two. This method catches about 77% of endometrial cancers.
If the biopsy is inconclusive or the ultrasound findings are concerning, a hysteroscopy may follow. This involves a small camera inserted into the uterus, allowing direct visualization of the lining and targeted tissue sampling. Hysteroscopy has a sensitivity of about 86% for detecting endometrial cancer and is particularly good at identifying polyps and other structural abnormalities that a blind biopsy might miss. A dilation and curettage procedure, where the lining is scraped more thoroughly, offers similar detection rates at around 88% sensitivity.
Why Early Detection Matters
The reason doctors take postmenopausal bleeding seriously, even though 91% of cases aren’t cancer, is that bleeding is often the very first symptom of endometrial cancer. About 90% of women eventually diagnosed with uterine cancer first noticed abnormal vaginal bleeding. That makes it an unusually reliable early warning sign.
When uterine cancer is caught at stage 1 or 2, before it has spread beyond the uterus, the five-year survival rate is 95%. That number drops sharply with later stages, falling to just 18% for stage 4 disease. The difference between those outcomes is largely a matter of timing. Women who get evaluated at the first sign of bleeding give themselves the best possible chance of catching a problem while it’s still highly treatable.
Most postmenopausal bleeding turns out to be nothing dangerous. Tissue thinning, polyps, hormonal shifts, and medications explain the vast majority of cases. But because the small percentage that is cancer responds so well to early treatment, getting checked promptly is one of the most straightforward ways to protect yourself.